Small GTPase R-Ras Regulates Integrity and Functionality of Tumor Blood Vessels

Cancer Cell

Volumn 22, Issue 2, 2012, Pages 235-249

  Sawada, Junko ^a   Urakami, Takeo ^a   Li, Fangfei ^a   Urakami, Akane ^a   Zhu, Weiquan ^b   Fukuda, Minoru ^a   Li, Dean Y ^b   Ruoslahti, Erkki ^a,c   Komatsu, Masanobu ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; MEMBRANE PROTEIN; R RAS PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; INTERNALIZATION; MOLECULAR INTERACTION; MORPHOGENESIS; MOUSE; NONHUMAN; PERFUSION; PERICYTE; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; UPREGULATION;

EID: 84865151156     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.06.013     Document Type: Article

References (37)

1. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., Porter D., Hu M., Chin L., Richardson A., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
2. Allingham M.J., van Buul J.D., Burridge K. ICAM-1-mediated, Src- and Pyk2-dependent vascular endothelial cadherin tyrosine phosphorylation is required for leukocyte transendothelial migration. J. Immunol. 2007, 179:4053-4064.
3. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008, 22:1276-1312.
4. Armulik A., Abramsson A., Betsholtz C. Endothelial/pericyte interactions. Circ. Res. 2005, 97:512-523.
5. Bao X., Moseman E.A., Saito H., Petryniak B., Thiriot A., Hatakeyama S., Ito Y., Kawashima H., Yamaguchi Y., Lowe J.B., et al. Endothelial heparan sulfate controls chemokine presentation in recruitment of lymphocytes and dendritic cells to lymph nodes. Immunity 2010, 33:817-829.
6. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 1999, 103:159-165.
7. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
8. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
9. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 2011, 10:417-427.
10. Coulon C., Georgiadou M., Roncal C., De Bock K., Langenberg T., Carmeliet P. From vessel sprouting to normalization: role of the prolyl hydroxylase domain protein/hypoxia-inducible factor oxygen-sensing machinery. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2331-2336.
11. Crosby C.V., Fleming P.A., Argraves W.S., Corada M., Zanetta L., Dejana E., Drake C.J. VE-cadherin is not required for the formation of nascent blood vessels but acts to prevent their disassembly. Blood 2005, 105:2771-2776.
12. Darland D.C., D'Amore P.A. Blood vessel maturation: vascular development comes of age. J. Clin. Invest. 1999, 103:157-158.
13. Dejana E., Orsenigo F., Lampugnani M.G. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J. Cell Sci. 2008, 121:2115-2122.
14. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
15. Fukuhara S., Sakurai A., Sano H., Yamagishi A., Somekawa S., Takakura N., Saito Y., Kangawa K., Mochizuki N. Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway. Mol. Cell. Biol. 2005, 25:136-146.
16. Gavard J., Gutkind J.S. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat. Cell Biol. 2006, 8:1223-1234.
17. Gerhardt H., Semb H. Pericytes: gatekeepers in tumour cell metastasis?. J. Mol. Med. 2008, 86:135-144.
18. Gory-Fauré S., Prandini M.H., Pointu H., Roullot V., Pignot-Paintrand I., Vernet M., Huber P. Role of vascular endothelial-cadherin in vascular morphogenesis. Development 1999, 126:2093-2102.
19. Heidenreich R., Kappel A., Breier G. Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor receptor-2 (Flk-1) promoter/enhancer sequences. Cancer Res. 2000, 60:6142-6147.
20. Helfrich I., Scheffrahn I., Bartling S., Weis J., von Felbert V., Middleton M., Kato M., Ergün S., Schadendorf D. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J. Exp. Med. 2010, 207:491-503.
21. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 2003, 9:685-693.
22. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
23. Kappel A., Rönicke V., Damert A., Flamme I., Risau W., Breier G. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood 1999, 93:4284-4292.
24. Kersting S., Konopke R., Kersting F., Volk A., Distler M., Bergert H., Saeger H.D., Grützmann R., Bunk A. Quantitative perfusion analysis of transabdominal contrast-enhanced ultrasonography of pancreatic masses and carcinomas. Gastroenterology 2009, 137:1903-1911.
25. Kinbara K., Goldfinger L.E., Hansen M., Chou F.L., Ginsberg M.H. Ras GTPases: integrins' friends or foes?. Nat. Rev. Mol. Cell Biol. 2003, 4:767-776.
26. Komatsu M., Ruoslahti E. R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis. Nat. Med. 2005, 11:1346-1350.
27. Lindahl P., Johansson B.R., Levéen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277:242-245.
28. Mancuso M.R., Davis R., Norberg S.M., O'Brien S., Sennino B., Nakahara T., Yao V.J., Inai T., Brooks P., Freimark B., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 2006, 116:2610-2621.
29. Mazzone M., Dettori D., Leite de Oliveira R., Loges S., Schmidt T., Jonckx B., Tian Y.M., Lanahan A.A., Pollard P., Ruiz de Almodovar C., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136:839-851.
30. McDonald D.M., Choyke P.L. Imaging of angiogenesis: from microscope to clinic. Nat. Med. 2003, 9:713-725.
31. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
32. Stupack D.G., Cheresh D.A. ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands. Sci. STKE 2002, 2002:pe7.
33. Thomas M., Augustin H.G. The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 2009, 12:125-137.
34. Weis S., Cui J., Barnes L., Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J. Cell Biol. 2004, 167:223-229.
35. Wu Z., Hofman F.M., Zlokovic B.V. A simple method for isolation and characterization of mouse brain microvascular endothelial cells. J. Neurosci. Methods 2003, 130:53-63.
36. Xu L., Komatsu M. Promoter cloning and characterization of the anti-vascular proliferation gene, R-ras: role of Ets- and Sp-binding motifs. J. Biol. Chem. 2009, 284:2706-2718.
37. Zhang Z., Vuori K., Wang H., Reed J.C., Ruoslahti E. Integrin activation by R-ras. Cell 1996, 85:61-69.